Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer

Fig. 1

Relationship between baseline plasma or tissue levels of IL-6 and clinical benefits of NSCLC patients after PD-1 inhibitors. A Baseline plasma concentration of circulating cytokines between patients with and without PD (PD and non-PD, respectively). B The distribution of baseline plasma IL-6 levels among patients exhibiting a PR, SD, and PD. C The distribution of baseline plasma IL-6 levels between the PD and non-PD patient cohorts. D, G ROC analysis of baseline plasma (D) and tissue (G) IL-6 levels for PFS of patients with NSCLC receiving ICIs in the CICAMS cohort. E, H Kaplan-Meier survival curve of PFS of patients with NSCLC receiving ICIs based on baseline plasma (E) and tissue (H) IL-6 levels. F, I Boxplots evaluating tumor response of NSCLC patients after PD-1 inhibitors between low and high plasma (F) and tissue (I) levels of IL-6 at baseline. sIL6: secreted IL-6

Back to article page